Dr. Post is Vivace’s chief scientific officer and a member of the board of directors, bringing more than three decades of pharmaceutical experience spanning companies of all sizes. Before joining Vivace in 2016, he served as chief scientific officer of BioMarin, a publicly held biopharmaceutical firm with a focus on rare diseases. He joined BioMarin when the company acquired LEAD Therapeutics, where he was CSO working with Dr. Qiao, and was responsible for inception as well as subsequent development of talazoparib until it was sold to Medivation by BioMarin. Positions prior to LEAD included senior vice president of research and development for Onyx Pharmacueticals and vice president of discovery research for Parke-Davis Pharmaceuticals. Dr. Post holds a doctorate in biochemistry from the University of Wisconsin and a B.S. in Chemistry from the University of Michigan.